II. Meşrutiyet Dönemi'nde Evkaf-ı Hümayun Nezareti'nde Bürokratik Reform

[No Abstract Available

Şura-yı Devlet

Şura-yı Devlet, memurlar ve kurumlar arasındaki uyum sürecini yasal metinler çerçevesinde buluşturan bir sürecin en önemli kilometre taşıdır. Ayrıca modern kamu idaresi ilkelerinin uygulanması ve idare hukukunun geliştirilmesine doğrudan katkıda bulunması bakımından yönetim anlayışımıza damgasını vurmuştur. Kuşkusuz her iki yönde işleyen süreç, imparatorluğun iç ve dış olayları ile engellenmiş ve durdurulmuştur. Elde edilen deneyimler, Cumhuriyet dönemi hukukçuları için benzersiz kazanımlar olarak görülmüş ve bu şekilde değerlendirilmiştir. Bu yazımızda II. Meşrutiyet döneminde Şura-yı Devletin yapısını, işlevini ve atama esaslarını ele aldık

Fever of unknown origin (FUO) on a land on cross-roads between Asia and Europa; a multicentre study from Turkey

Aims The differential diagnosis of Fever of Unknown Origin (FUO) is still a major clinical challenge despite the advances in diagnostic procedures. In this multicentre study, we aimed to reveal FUO aetiology and factors influencing the final diagnosis of FUO in Turkey

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study

Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile

Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?

Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by CF transmembrane conductance regulator (CFTR) genetic variants. CFTR modulators improve pulmonary function and reduce respiratory infections in CF. This study investigated the clinical and laboratory follow-up parameters over 1 year in patients with CF who could not receive this treatment. Methods: This retrospective cohort study included 2018 and 2019 CF patient data from the CF registry of Turkey. Demographic and clinical characteristics of 294 patients were assessed, who had modulator treatment indications in 2018 but could not reach the treatment. Results: In 2019, patients younger than 18 years had significantly lower BMI z-scores than in 2018. During the 1-year follow-up, forced expiratory volumes (FEV1) and FEV1 z-scores a trend toward a decrease. In 2019, chronic Staphylococcus aureus colonization, inhaled antipseudomonal antibiotic use for more than 3 months, oral nutritional supplement requirements, and oxygen support need increased. Conclusions: Patients who had indications for modulator treatments but were unable to obtain them worsened even after a year of follow-up. This study emphasized the importance of using modulator treatments for patients with CF in our country, as well as in many countries worldwide